Welcome to our dedicated page for Heartflow SEC filings (Ticker: HTFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Heartflow, Inc. filings document a Nasdaq-listed Delaware medical technology company focused on AI software for coronary artery disease. Its recent 8-K reports furnish operating results, investor presentations and Regulation FD disclosures, while also recording capital-structure events tied to its completed initial public offering and repayment and termination of a credit agreement.
The company’s proxy materials cover annual meeting matters, director elections, auditor ratification and stockholder voting mechanics. As an emerging growth company, Heartflow’s filings also identify governance, exchange listing, financial reporting and public-company status disclosure areas relevant to a commercial-stage medical technology issuer.
Heartflow, Inc. (HTFL) reported that its Chief Executive Officer and director, John C.M. Farquhar, sold 27,230 shares of Common Stock on August 21, 2026 at a price of $50.00 per share in an open-market or private transaction. After this sale, he held 360,814 shares directly. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025.
Heartflow, Inc. (HTFL) insider John C. M. Farquhar has filed a notice under Rule 144 to sell up to 27,230 shares of Heartflow common stock. The proposed sale, to be executed through Fidelity Brokerage Services LLC, relates to a stock option exercise for cash on 06/24/2024.
The filing reports an aggregate market value of approximately $1,361,500.00 for the shares covered, with Heartflow having 86,953,627 shares outstanding of common stock. It also lists multiple prior common stock sales by Farquhar over the past three months, each with stated share counts and dollar amounts.
Heartflow, Inc. (HTFL) reported that Chief Executive Officer and director John C.M. Farquhar sold 32,676 shares of Common Stock in a sale transaction on August 18, 2026 at $45.00 per share, described as a sale in an open market or private transaction. After this transaction, he directly held 388,044 shares of Common Stock. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Farquhar on September 12, 2025.
Heartflow, Inc. (HTFL) reported that Chief Medical Officer Campbell Rogers exercised stock options for 9,219 shares of common stock at an exercise price of $19.00 per share and sold the same 9,219 shares at $41.23 per share on August 17, 2026. The option position had 82,972 options remaining after the exercise and continues to vest monthly until August 7, 2029, with an expiration date of August 7, 2035. These transactions were effected under a Rule 10b5-1 Trading Plan adopted on December 12, 2025. Rogers also reports indirect holdings of common stock through various trusts, including 22,615; 46,159; 26,012; and 50,754 shares, respectively.
Heartflow, Inc. (HTFL) reported that Chief Executive Officer John C.M. Farquhar sold 15,560 shares of common stock on August 14, 2026 at $39.06 per share in an open-market or private transaction. After this sale, he directly holds 420,720 shares of Heartflow common stock. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025.
Heartflow, Inc. (HTFL) is the issuer for a planned resale of its common stock by stockholder John C.M. Farquhar under Rule 144. The notice lists 32,676 shares of common stock, associated with a stock option exercise on 06/24/2024, to be sold through Fidelity Brokerage Services LLC on NASDAQ.
The filing also discloses prior sales of Heartflow common stock by the same holder during the past three months, including transactions of 22,562, 38,900, 22,562, 22,562, and 15,560 shares on various dates in June, July, and August 2026, with corresponding dollar amounts reported as sale values.
HTFL insider Campbell D. Rogers filed a notice to sell common stock. The planned transaction involves 9,219 shares of common stock, linked to a Stock Option Exercise expected on 08/17/2026, with sales to be executed in cash through Fidelity Brokerage Services LLC on NASDAQ.
Rogers previously sold 9,219 shares of common stock on 05/18/2026 for $261,266.46 and another 9,219 shares on 07/15/2026 for $237,112.68. The current planned sale of 9,219 shares is reported with an aggregate market value of $380,099.37.
A holder of HTFL common stock filed to potentially sell up to 200,000 shares through UBS Financial Services Inc. on NASDAQ, with an aggregate market value of $8,434,000.00. Total common shares outstanding are 86,398,778.
The filing also reports an in-kind distribution of 629,804 shares from HCPCIV 1 LLC dated March 30, 2026, listed among securities sold during the past three months.
HTFL shareholder John C.M. Farquhar filed to sell 15,560 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an approximate value of $607,773.60. The shares relate to a stock option exercise dated 06/25/2024, to be settled in cash. The filing also lists prior sales over the past three months, including 22,562 shares for $643,017.00 on 06/10/2026, 38,900 shares for $1,361,500.00 on 06/24/2026, 22,562 shares for $626,095.50 on 07/10/2026, and 22,562 shares for $638,730.22 on 08/10/2026.